• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[血液学参数对前列腺特异性抗原水平处于灰色地带的前列腺癌患者的诊断价值]

[Diagnostic value of hematological parameters for prostate cancer in patients with gray-zone prostate-specific antigen levels].

作者信息

Ge Peng, Zheng Yu-Xin, Yan Zi-Rong, Li Liang, Li Wang, Wang Jun-Qi

机构信息

Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.

Department of Urology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221006, China.

出版信息

Zhonghua Nan Ke Xue. 2024 Aug;30(8):701-708.

PMID:40778795
Abstract

OBJECTIVE

To evaluate the diagnostic value of hematological parameters for PCa with prostate-specific antigen (PSA) of 4-10 μg/L and construct a risk-stratification model with these parameters.

METHODS

We retrospectively analyzed the data on the males undergoing the initial prostatic biopsy in the Affiliated Hospital of Xuzhou Medical University with PSA of 4-10 μg/L from March 2010 to April 2021. According to the results of biopsy, we classified the patients into a PCa and a non-PCa group, and compared the hematological parameters between the two groups. We performed univariate and multivariate logistic regression analyses, identified the independent risk factors for PCa, constructed a risk-stratification model for the prediction of PCa and evaluated its efficiency.

RESULTS

A total of 415 cases were included in this study, 107 (25.8%) in the PCa and 308 (74.2%) in the non-PCa group. Compared with the non-PCa males, the PCa patients showed a significantly older age, higher ratios of neutrophil to lymphocyte and platelet to lymphocyte, systemic immune-inflammation index (SII), red blood cell distribution width and cystatin C (CysC) level (all P<0.05), but lower red blood cell count and hemoglobin and free/total PSA (f/tPSA) levels (all P<0.05). Multivariate logistic regression analysis indicated that age, f/tPSA, SII and CysC were independent risk factors for the prediction of PCa (all P<0.05). Five prediction models were constructed based on the above risk factors, and the area under the ROC curve (AUC) of the four-parameter (age+f/tPSA+SII+CysC) model was 0.745 (95% CI: 0.694-0.796), significantly higher than those of the other models (P<0.05). A risk-stratification model (low-, intermediate-, and high-risk) was also constructed based on the total nomogram scores, which showed a comparable performance to that of the Prostate Imaging Reporting and Data System (PI-RADS) for the prediction of PCa (AUC: 0.727 [95% CI: 0.650-0.804] vs 0.734 [95% CI: 0.658-0.811]). However, the prediction rate by the risk-stratification model was evidently higher in the low-risk males than in those with low PI-RADS scores (1-2) (39.4% vs 22.2%).

CONCLUSION

SII and CysC are independent risk factors for the prediction of PCa in patients with gray-zone PSA levels. The risk-stratification model based on age, SII, CysC and f/tPSA is comparable to PI-RADS in the diagnostic efficiency of PCa, with an even higher prediction rate in low-risk patients than in those with low PI-RADS scores, and contributive to precision screening and reduction of excessive biopsies in the diagnosis of PCa with gray-zone PSA.

摘要

目的

评估血液学参数对前列腺特异性抗原(PSA)为4-10 μg/L的前列腺癌(PCa)的诊断价值,并构建基于这些参数的风险分层模型。

方法

回顾性分析2010年3月至2021年4月在徐州医科大学附属医院接受初次前列腺穿刺活检、PSA为4-10 μg/L的男性患者数据。根据活检结果,将患者分为PCa组和非PCa组,比较两组的血液学参数。进行单因素和多因素logistic回归分析,确定PCa的独立危险因素,构建预测PCa的风险分层模型并评估其效能。

结果

本研究共纳入415例患者,PCa组107例(25.8%),非PCa组308例(74.2%)。与非PCa男性相比,PCa患者年龄显著更大,中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、全身免疫炎症指数(SII)、红细胞分布宽度和胱抑素C(CysC)水平更高(均P<0.05),但红细胞计数、血红蛋白和游离/总PSA(f/tPSA)水平更低(均P<0.05)。多因素logistic回归分析表明,年龄、f/tPSA、SII和CysC是预测PCa的独立危险因素(均P<0.05)。基于上述危险因素构建了5个预测模型,四参数(年龄+f/tPSA+SII+CysC)模型的ROC曲线下面积(AUC)为0.745(95%CI:0.694-0.796),显著高于其他模型(P<0.05)。还基于总列线图评分构建了一个风险分层模型(低、中、高风险),其在预测PCa方面的表现与前列腺影像报告和数据系统(PI-RADS)相当(AUC:0.727[95%CI:0.650-0.804]vs 0.734[95%CI:0.658-0.811])。然而,风险分层模型在低风险男性中的预测率明显高于PI-RADS评分低(1-2分)的男性(39.4%对22.2%)。

结论

SII和CysC是预测灰区PSA水平患者PCa的独立危险因素。基于年龄、SII、CysC和f/tPSA的风险分层模型在PCa诊断效能上与PI-RADS相当,在低风险患者中的预测率甚至高于PI-RADS评分低的患者,有助于PCa灰区PSA诊断中的精准筛查和减少过度活检。

相似文献

1
[Diagnostic value of hematological parameters for prostate cancer in patients with gray-zone prostate-specific antigen levels].[血液学参数对前列腺特异性抗原水平处于灰色地带的前列腺癌患者的诊断价值]
Zhonghua Nan Ke Xue. 2024 Aug;30(8):701-708.
2
Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?前列腺影像报告和数据系统第 2 版能否减少 PSA 水平在 4-10ng/ml 的男性进行不必要的前列腺活检?
J Cancer Res Clin Oncol. 2018 May;144(5):987-995. doi: 10.1007/s00432-018-2616-6. Epub 2018 Mar 5.
3
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
[A preoperative prediction model for pelvic lymph node metastasis in prostate cancer: Integrating clinical characteristics and multiparametric MRI].[一种前列腺癌盆腔淋巴结转移的术前预测模型:整合临床特征和多参数磁共振成像]
Beijing Da Xue Xue Bao Yi Xue Ban. 2025 Aug 18;57(4):684-691. doi: 10.19723/j.issn.1671-167X.2025.04.009.
6
PSA proportion of index lesion: a novel index for predicting prostate pathology outcomes in biopsy-naïve patients with PSA < 10 ng/ml and PI-RADS 3 lesions.索引病灶的前列腺特异性抗原比例:预测前列腺特异抗原小于10纳克/毫升且PI-RADS 3类病灶的未接受活检患者前列腺病理结果的新指标。
World J Urol. 2025 Jul 17;43(1):444. doi: 10.1007/s00345-025-05810-2.
7
Exploration of the diagnostic capacity of PSAMR combined with PI-RADS scoring for clinically significant prostate cancer and establishment and validation of the Nomogram prediction model.探讨 PSAMR 联合 PI-RADS 评分对临床显著前列腺癌的诊断能力,并建立和验证列线图预测模型。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11309-11317. doi: 10.1007/s00432-023-05008-2. Epub 2023 Jun 27.
8
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
9
A strategy to reduce unnecessary prostate biopsies in patients with tPSA >10 ng ml -1 and PI-RADS 1-3.一项针对总前列腺特异抗原(tPSA)>10 ng/ml且前列腺影像报告和数据系统(PI-RADS)为1-3级患者减少不必要前列腺活检的策略。
Asian J Androl. 2025 Jul 1;27(4):531-536. doi: 10.4103/aja202499. Epub 2025 Jan 28.
10
Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening.将既往病史和生活方式数据与鞘脂水平相结合用于基于风险的前列腺癌筛查。
J Transl Med. 2025 Jul 14;23(1):790. doi: 10.1186/s12967-025-06820-9.